Genotype effects of CHRNA7, CNRI and COMT in schizophrenia: Interactions with tobacco and cannabis use

Stanley Zammit, Gillian Spurlock, Hywel Williams, Nadine Norton, Nigel Williams, Michael C. O'Donovan, Michael J. Owen

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Background: Genetic variations might modify associations between schizophrenia and cannabis or tobacco use. Aims: To examine whether variants within the cannabinoid receptor (CNRI) and α7 nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use. We also examined a putative interaction between cannabis and Val158Met within the catechol-O-methyltransferase gene (COMT). Method: Genotype effects of CHRNA7 and CNRI were studied in a case-control sample of 750 individuals with schizophrenia and 688 controls, with interactions for these genes studied in small subsamples. A case-only design of 493 of the schizophrenia group was used to examine interactions between cannabis use and COMT. Results: There was no evidence of association between schizophrenia and CNRI (OR=0.97, 9596 CI 0.82-1.13) or CHRNA7 (OR=1,07, 95% CI 0.77-1.49) genotypes, or of interactions between tobacco use and CHRNA7, or cannabis use and CNRI or COMT genotypes. Conclusions: Neither CNRI nor CHRNA7 variation appears to alter the risk of schizophrenia. Furthermore, our results do not support the presence of different effects of cannabis use on schizophrenia according to variation within COMT.

Original languageEnglish (US)
Pages (from-to)402-407
Number of pages6
JournalBritish Journal of Psychiatry
Volume191
Issue numberNOV.
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Catechol O-Methyltransferase
Tobacco Use
Cannabis
Schizophrenia
Genotype
Genes
Cannabinoid Receptors
Nicotinic Receptors

ASJC Scopus subject areas

  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Genotype effects of CHRNA7, CNRI and COMT in schizophrenia : Interactions with tobacco and cannabis use. / Zammit, Stanley; Spurlock, Gillian; Williams, Hywel; Norton, Nadine; Williams, Nigel; O'Donovan, Michael C.; Owen, Michael J.

In: British Journal of Psychiatry, Vol. 191, No. NOV., 11.2007, p. 402-407.

Research output: Contribution to journalArticle

Zammit, Stanley ; Spurlock, Gillian ; Williams, Hywel ; Norton, Nadine ; Williams, Nigel ; O'Donovan, Michael C. ; Owen, Michael J. / Genotype effects of CHRNA7, CNRI and COMT in schizophrenia : Interactions with tobacco and cannabis use. In: British Journal of Psychiatry. 2007 ; Vol. 191, No. NOV. pp. 402-407.
@article{b29ec38810e84f788e78f910c1faebc3,
title = "Genotype effects of CHRNA7, CNRI and COMT in schizophrenia: Interactions with tobacco and cannabis use",
abstract = "Background: Genetic variations might modify associations between schizophrenia and cannabis or tobacco use. Aims: To examine whether variants within the cannabinoid receptor (CNRI) and α7 nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use. We also examined a putative interaction between cannabis and Val158Met within the catechol-O-methyltransferase gene (COMT). Method: Genotype effects of CHRNA7 and CNRI were studied in a case-control sample of 750 individuals with schizophrenia and 688 controls, with interactions for these genes studied in small subsamples. A case-only design of 493 of the schizophrenia group was used to examine interactions between cannabis use and COMT. Results: There was no evidence of association between schizophrenia and CNRI (OR=0.97, 9596 CI 0.82-1.13) or CHRNA7 (OR=1,07, 95{\%} CI 0.77-1.49) genotypes, or of interactions between tobacco use and CHRNA7, or cannabis use and CNRI or COMT genotypes. Conclusions: Neither CNRI nor CHRNA7 variation appears to alter the risk of schizophrenia. Furthermore, our results do not support the presence of different effects of cannabis use on schizophrenia according to variation within COMT.",
author = "Stanley Zammit and Gillian Spurlock and Hywel Williams and Nadine Norton and Nigel Williams and O'Donovan, {Michael C.} and Owen, {Michael J.}",
year = "2007",
month = "11",
doi = "10.1192/bjp.bp.107.036129",
language = "English (US)",
volume = "191",
pages = "402--407",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "NOV.",

}

TY - JOUR

T1 - Genotype effects of CHRNA7, CNRI and COMT in schizophrenia

T2 - Interactions with tobacco and cannabis use

AU - Zammit, Stanley

AU - Spurlock, Gillian

AU - Williams, Hywel

AU - Norton, Nadine

AU - Williams, Nigel

AU - O'Donovan, Michael C.

AU - Owen, Michael J.

PY - 2007/11

Y1 - 2007/11

N2 - Background: Genetic variations might modify associations between schizophrenia and cannabis or tobacco use. Aims: To examine whether variants within the cannabinoid receptor (CNRI) and α7 nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use. We also examined a putative interaction between cannabis and Val158Met within the catechol-O-methyltransferase gene (COMT). Method: Genotype effects of CHRNA7 and CNRI were studied in a case-control sample of 750 individuals with schizophrenia and 688 controls, with interactions for these genes studied in small subsamples. A case-only design of 493 of the schizophrenia group was used to examine interactions between cannabis use and COMT. Results: There was no evidence of association between schizophrenia and CNRI (OR=0.97, 9596 CI 0.82-1.13) or CHRNA7 (OR=1,07, 95% CI 0.77-1.49) genotypes, or of interactions between tobacco use and CHRNA7, or cannabis use and CNRI or COMT genotypes. Conclusions: Neither CNRI nor CHRNA7 variation appears to alter the risk of schizophrenia. Furthermore, our results do not support the presence of different effects of cannabis use on schizophrenia according to variation within COMT.

AB - Background: Genetic variations might modify associations between schizophrenia and cannabis or tobacco use. Aims: To examine whether variants within the cannabinoid receptor (CNRI) and α7 nicotinic receptor (CHRNA7) genes are associated with schizophrenia, and whether these effects vary according to cannabis or tobacco use. We also examined a putative interaction between cannabis and Val158Met within the catechol-O-methyltransferase gene (COMT). Method: Genotype effects of CHRNA7 and CNRI were studied in a case-control sample of 750 individuals with schizophrenia and 688 controls, with interactions for these genes studied in small subsamples. A case-only design of 493 of the schizophrenia group was used to examine interactions between cannabis use and COMT. Results: There was no evidence of association between schizophrenia and CNRI (OR=0.97, 9596 CI 0.82-1.13) or CHRNA7 (OR=1,07, 95% CI 0.77-1.49) genotypes, or of interactions between tobacco use and CHRNA7, or cannabis use and CNRI or COMT genotypes. Conclusions: Neither CNRI nor CHRNA7 variation appears to alter the risk of schizophrenia. Furthermore, our results do not support the presence of different effects of cannabis use on schizophrenia according to variation within COMT.

UR - http://www.scopus.com/inward/record.url?scp=35948986314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948986314&partnerID=8YFLogxK

U2 - 10.1192/bjp.bp.107.036129

DO - 10.1192/bjp.bp.107.036129

M3 - Article

C2 - 17978319

AN - SCOPUS:35948986314

VL - 191

SP - 402

EP - 407

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - NOV.

ER -